Prognostic factors for survival identified by multivariate analysis in older patients with AML
| . | Groups . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Age, y | ≥ 70 | 1.289 | 1.082-1.536 | .004 |
| 65-69 | 1 | |||
| ECOG performance status | > 2 | 2.095 | 1.428-3.073 | < .001 |
| 0-2 | 1 | |||
| Poor-risk cytogenetics | −7, −5, and/or complex | 1.866 | 1.566-2.224 | < .001 |
| Other | 1 | |||
| BM blasts | ≤ 47% | 1.006 | 0.875-1.260 | .60 |
| > 47% | 1 | |||
| Creatinine, mg/dL | ≥ 1.5 | 1.640 | 1.286-2.090 | < .001 |
| < 1.5 | 1 | |||
| Peripheral blood blasts | ≤ 13% | 0.651 | 0.544-0.779 | < .001 |
| > 13% | 1 | |||
| Hemoglobin, g/dL | ≤ 8 | 1.177 | 0.996-1.391 | .055 |
| > 8 | 1 | |||
| Type of therapy | Epigenetic | 1.116 | 0.895-1.391 | .330 |
| Chemotherapy | 1 |
| . | Groups . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Age, y | ≥ 70 | 1.289 | 1.082-1.536 | .004 |
| 65-69 | 1 | |||
| ECOG performance status | > 2 | 2.095 | 1.428-3.073 | < .001 |
| 0-2 | 1 | |||
| Poor-risk cytogenetics | −7, −5, and/or complex | 1.866 | 1.566-2.224 | < .001 |
| Other | 1 | |||
| BM blasts | ≤ 47% | 1.006 | 0.875-1.260 | .60 |
| > 47% | 1 | |||
| Creatinine, mg/dL | ≥ 1.5 | 1.640 | 1.286-2.090 | < .001 |
| < 1.5 | 1 | |||
| Peripheral blood blasts | ≤ 13% | 0.651 | 0.544-0.779 | < .001 |
| > 13% | 1 | |||
| Hemoglobin, g/dL | ≤ 8 | 1.177 | 0.996-1.391 | .055 |
| > 8 | 1 | |||
| Type of therapy | Epigenetic | 1.116 | 0.895-1.391 | .330 |
| Chemotherapy | 1 |
HR indicates hazard ratio; and CI, confidence interval.